Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus.

Ebert G, Preston S, Allison C, Cooney J, Toe JG, Stutz MD, Ojaimi S, Scott HW, Baschuk N, Nachbur U, Torresi J, Chin R, Colledge D, Li X, Warner N, Revill P, Bowden S, Silke J, Begley CG, Pellegrini M.

Proc Natl Acad Sci U S A. 2015 May 5;112(18):5797-802. doi: 10.1073/pnas.1502390112. Epub 2015 Apr 20.

2.

Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries.

Cambiano V, Ford D, Mabugu T, Napierala Mavedzenge S, Miners A, Mugurungi O, Nakagawa F, Revill P, Phillips A.

J Infect Dis. 2015 Aug 15;212(4):570-7. doi: 10.1093/infdis/jiv040. Epub 2015 Mar 12.

3.

Improving survival of retinoblastoma in Uganda.

Waddell KM, Kagame K, Ndamira A, Twinamasiko A, Picton SV, Simmons IG, Revill P, Johnston WT, Newton R.

Br J Ophthalmol. 2015 Jul;99(7):937-42. doi: 10.1136/bjophthalmol-2014-306206. Epub 2015 Jan 12.

PMID:
25583281
4.

Opportunities for improving the efficiency of paediatric HIV treatment programmes.

Revill PA, Walker S, Mabugu T, Nathoo KJ, Mugyenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahirya-Ntege P, Walker AS, Sculpher MJ, Gibb DM.

AIDS. 2015 Jan 14;29(2):201-10. doi: 10.1097/QAD.0000000000000518.

5.

Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.

Phillips A, Cambiano V, Nakagawa F, Magubu T, Miners A, Ford D, Pillay D, De Luca A, Lundgren J, Revill P.

PLoS One. 2014 Oct 7;9(10):e109148. doi: 10.1371/journal.pone.0109148. eCollection 2014.

6.

The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe.

Chan AK, Ford D, Namata H, Muzambi M, Nkhata MJ, Abongomera G, Mambule I, South A, Revill P, Grundy C, Mabugu T, Chiwaula L, Cataldo F, Hakim J, Seeley J, Kityo C, Reid A, Katabira E, Sodhi S, Gilks CF, Gibb DM; Lablite Team.

BMC Health Serv Res. 2014 Aug 19;14:352. doi: 10.1186/1472-6963-14-352.

7.

Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.

Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Kessler J, Menzies NA, Nucifora KA, Vizcaya LS, Walker S, Welte A, Easterbrook P, Doherty M, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e35-43. doi: 10.1016/S2214-109X(13)70048-2. Epub 2013 Dec 10.

8.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e23-34. doi: 10.1016/S2214-109X(13)70172-4. Epub 2013 Dec 10.

9.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2013 Dec 10;2(1):23-34.

10.

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team.

Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.

11.

Viral factors and predicting disease outcomes in chronic hepatitis B.

Revill P, Locarnini S.

Gut. 2015 Feb;64(2):191-3. doi: 10.1136/gutjnl-2014-307398. Epub 2014 Jun 11. No abstract available.

PMID:
24920075
12.

Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients.

Lesmana CR, Jackson K, Lim SG, Sulaiman A, Pakasi LS, Gani RA, Hasan I, Sulaiman AS, Lesmana LA, Hammond R, Revill P, Locarnini S, Bowden SD.

United European Gastroenterol J. 2014 Apr;2(2):99-107. doi: 10.1177/2050640614525151.

13.

Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen.

Jegaskanda S, Ahn SH, Skinner N, Thompson AJ, Ngyuen T, Holmes J, De Rose R, Navis M, Winnall WR, Kramski M, Bernardi G, Bayliss J, Colledge D, Sozzi V, Visvanathan K, Locarnini SA, Kent SJ, Revill PA.

J Virol. 2014 Sep;88(18):10412-20. doi: 10.1128/JVI.00111-14. Epub 2014 May 28.

14.

Using modeling to inform international guidelines for antiretroviral treatment.

Hallett TB, Menzies NA, Revill P, Keebler D, Bórquez A, McRobie E, Eaton JW.

AIDS. 2014 Jan;28 Suppl 1:S1-4. doi: 10.1097/QAD.0000000000000115. No abstract available.

PMID:
24468942
15.

Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?

Penazzato M, Revill P, Prendergast AJ, Collins IJ, Walker S, Elyanu PJ, Sculpher M, Gibb DM.

Lancet Infect Dis. 2014 Jul;14(7):650-5. doi: 10.1016/S1473-3099(13)70262-7. Epub 2014 Jan 21. Review.

PMID:
24456814
16.

Strategies for efficient computation of the expected value of partial perfect information.

Madan J, Ades AE, Price M, Maitland K, Jemutai J, Revill P, Welton NJ.

Med Decis Making. 2014 Apr;34(3):327-42. doi: 10.1177/0272989X13514774. Epub 2014 Jan 21.

PMID:
24449434
17.

Antiretroviral therapy recommendations for the global community: aspiration versus reality.

Phillips AN, Munderi P, Revill PA, El-Sadr WM, Lundgren JD.

AIDS. 2014 Apr 24;28(7):939-41. doi: 10.1097/QAD.0000000000000171. No abstract available.

PMID:
24378756
18.

Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma.

Bayliss J, Lim L, Thompson AJ, Desmond P, Angus P, Locarnini S, Revill PA.

J Hepatol. 2013 Nov;59(5):1022-8. doi: 10.1016/j.jhep.2013.06.018. Epub 2013 Jun 25.

PMID:
23811301
19.

Advances in the molecular diagnosis of hepatitis B infection: providing insight into the next generation of disease.

Bayliss J, Nguyen T, Lesmana CR, Bowden S, Revill P.

Semin Liver Dis. 2013 May;33(2):113-21. doi: 10.1055/s-0033-1345714. Epub 2013 Jun 8. Review.

PMID:
23749667
20.

Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype.

Li W, Warner N, Sozzi V, Yuen L, Colledge D, Li T, Zhuang H, Locarnini S, Revill PA.

Hepatol Int. 2013 Jun;7(2):443-50. doi: 10.1007/s12072-012-9411-2. Epub 2012 Nov 28.

PMID:
26201776
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk